

68. Perucho, M. Cancer of the microsatellite mutator phenotype. *Biol. Chem.* **377**, 675–684 (1996).
69. Samowitz, W. S. & Slattery, M. L. Transforming growth factor- β receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. *Am. J. Pathol.* **151**, 33–35 (1997).
70. Sedivy, R. *et al.* Genetic analysis of multiple synchronous lesions of the colon adenoma–carcinoma sequence. *Br. J. Cancer* **82**, 1276–1282 (2000).
71. Yashiro, M. *et al.* Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. *Cancer Res.* **61**, 2676–2683 (2001).
72. Boland, C. R. *et al.* A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* **58**, 5248–5257 (1998).
73. Hornfray, T. F. *et al.* Defects in mismatch repair occur after APC mutations in the pathogenesis of sporadic colorectal tumours. *Hum. Mutat.* **11**, 114–120 (1998).
74. Hawkins, N. J., Tomlinson, I., Meagher, A. & Ward, R. L. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. *Br. J. Cancer* **84**, 232–236 (2001).
75. Humar, B. *et al.* Novel germline *CDH1* mutations in hereditary diffuse gastric cancer families. *Hum. Mutat.* **19**, 518–525 (2002).
76. Yabuta, T. *et al.* E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. *Int. J. Cancer* **101**, 434–441 (2002).
77. Suriano, G. *et al.* Identification of *CDH1* germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. *Hum. Mol. Genet.* **12**, 575–582 (2003).
78. Shtil, A. A. Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention. *J. Hematother. Stem Cell Res.* **11**, 231–241 (2002).
79. Dalton, W. S. Drug resistance and drug development in multiple myeloma. *Semin. Oncol.* **29**, 21–25 (2002).
80. Naito, S., Yokomizo, A. & Koga, H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. *Int. J. Urol.* **6**, 427–439 (1999).
81. Lamlum, H. *et al.* The type of somatic mutation at *APC* in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. *Nature Med.* **5**, 1071–1075 (1999).
82. Crabtree, M. *et al.* Refining the relationship between 'first hits' and 'second hits' at the *APC* locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. *Oncogene* **22**, 4257–4265 (2003).
83. Albuquerque, C. *et al.* The 'just-right' signaling model: *APC* somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. *Hum. Mol. Genet.* **11**, 1549–1560 (2002).
84. Toyota, M., Ohe-Toyota, M., Ahuja, N. & Issa, J. P. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. *Proc. Natl Acad. Sci. USA* **97**, 710–715 (2000).
85. Menigatti, M. *et al.* Methylation pattern of different regions of the *MLH1* promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. *Genes Chromosom. Cancer* **31**, 357–361 (2001).
86. Simpson, D. J., Bicknell, J. E., McNicol, A. M., Clayton, R. N. & Farrell, W. E. Hypermethylation of the *p16/CDKN2A/MTS1* gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. *Genes Chromosom. Cancer* **24**, 328–336 (1999).
87. Wheeler, J. M., Loukola, A., Aaltonen, L. A., Mortensen, N. J. & Bodmer, W. F. The role of hypermethylation of the *hMLH1* promoter region in HNPCC versus MSI⁺ sporadic colorectal cancers. *J. Med. Genet.* **37**, 588–592 (2000).
88. Spirio, L. N. *et al.* Alleles of *APC* modulate the frequency and classes of mutations that lead to colon polyps. *Nature Genet.* **20**, 385–388 (1998).
89. Birch, J. M. *et al.* Cancer phenotype correlates with constitutional *TP53* genotype in families with the Li–Fraumeni syndrome. *Oncogene* **17**, 1061–1068 (1998).

Acknowledgements

We are grateful to W. Bodmer for consistently thought-provoking discussion, and to many others in the field (J. Cairns, P. Nowell, L. Loeb, B. Vogelstein and others) with whom we might or might not always agree, but whose views continue to provide challenges and food for thought. The authors are supported by Cancer Research UK and grants from the Boehringer Ingelheim Fonds (to O.M.S.) and the Swiss National Science Foundation (to K.H.).

Online links

DATABASES

The following terms in this article are linked online to:

Cancer.gov: <http://cancer.gov/>
Colorectal cancer | endometrial cancer
LocusLink: <http://www.ncbi.nlm.nih.gov/LocusLink/APC|BUB1|KRAS|MLH1|MSH2|MYH|PTEN|SMAD4|TP53>

FURTHER INFORMATION

The Jackson Laboratory: <http://jaxmice.jax.org/>
The p53 web site at L'Institut Curie: <http://perso.curie.fr/Thierry.Soussi/APC.html>
Access to this interactive links box is free online.

CORRECTION

RAS ONCOGENES: THE FIRST 30 YEARS

Marcos Malumbres and Mariano Barbacid

Nature Reviews Cancer **3**, 459–465 (2003)

On page 462 of this article, the group of Chris Marshall should have been credited, alongside those of Jasper Rine and Sang–Ho Kim, with the discovery of RAS isoprenylation. The text and references should have been:

In two landmark papers published in 1989 (REFS 85,86), the groups of Chris Marshall and of Jasper Rine, the latter in collaboration with Sang–Ho Kim, described isoprenylation as a novel mechanism of post-translational modification of proteins, which allowed them to identify the biochemical basis for the attachment of RAS proteins to membranes.

85. Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. *Cell* **57**, 1167–1177 (1989).

86. Schafer, W. R. *et al.* Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. *Science* **245**, 379–385 (1989).